{"url_path":"/sec/cik-0001567892/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-073787-index.html","accession_number":"0001104659-26-073787","cik":"0001567892","ticker":null,"issuer_name":"Keenova Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-073787-index.html","primary_entity_key":"0001567892","primary_entity_name":"Keenova Therapeutics plc"},"word_count":148,"has_tables":true,"body_markdown":"**Item 8.01.****Other Events.**\n\n \n\nOn June 13, 2026, Keenova Therapeutics plc (“Keenova”)\nentered into a purchase agreement with Par Health, Inc. (the “Purchaser”), pursuant to which Keenova has agreed to sell\nits Percocet and Endocet businesses (the “Business”) to Purchaser. Consideration for the transaction is expected to total\napproximately $250 million consisting of an upfront purchase price of $25 million, subject to customary adjustments for cash, debt and\nworking capital, and quarterly earnout payments payable in cash, related to the gross profit of the Business over a period of five years\nfollowing the closing of the transaction. The transaction is expected to close in the third quarter of 2026, subject to satisfaction of\ncustomary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Act. Following\nclosing of the transaction and completion of related obligations, Keenova will no longer market, manufacture or distribute opioid products."}